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Introduction
Effective interventions are available for general
practitioners (GPs) to reduce unwarranted long-
term benzodiazepine use (13). A majority of GPs
report the intention to critically discuss discontinua-
tion of long-term benzodiazepine use with their
patients but neglect to effectuate this intention (4).
Therefore, GPs’ experiences with the feasibility of
these interventions are crucial for successful imple-
mentation.
Methods
A postal survey was conducted exploring the opi-
nions and experiences of 56 GPs (working in
30 general practices) with the feasibility of a stepwise
benzodiazepine reduction programme (the Benzo-
redux programme) (5,6). The questionnaire (avail-
able on request) was sent 2 months after the end of
the second and last intervention. It consisted of
23 statements that had to be rated on a five-point
Likert scale (afterwards recoded on a three-point
scale: agree, neutral, disagree), six dichotomous yes/
no questions with room for explanation, and four
open questions.
The programme was carried out between August
1998 and December 2001 (Figure 1). First, we
identified all patients that had used benzodiazepines
for over 3 months (n2964), who were subse-
quently checked by their GPs for inclusion and
exclusion criteria. As the first intervention, we sent
a personal discontinuation letter (n2004). Three
months later, subjects were invited by letter (and
telephone in case of no response) for an evaluation
consultation. During this evaluation consultation,
GPs motivated non-quitters to participate in the
second intervention by using conversational advice
derived from the stages-of-change concept (7). Of
the non-quitters, only 180 patients took part in this
second intervention consisting of a three-group
randomized trial comparing tapering off supervised
by the GPs, with and without five additional sessions
of group psychotherapy, with a usual-care control
group. In both active treatment groups, patients
visited their GPs six times to reduce their benzodia-
zepine dosage by 25% per week after being trans-
ferred to an equivalent dosage of diazepam.
Abstinence was achieved by one-quarter of the
patients after the discontinuation letter and by two-
thirds after tapering off. During the 1521-month
follow-up, half of all quitters remained completely
abstinent (5,6,8,9).
Results
We received responses from 55 of the 56 general
practitioners (98%). According to normal-sized
Dutch practice (2350 patients), we identified an
average of 59 long-term benzodiazepine users, of
whom 40 received the discontinuation letter. GPs
needed less than 5 min per patient to check exclu-
sion criteria and 15 min for an evaluation consulta-
tion. The GPs reported that, in general, patients
reacted positively about the discontinuation letter;
30 GPs (58%) had at least one patient who gave a
strikingly positive reaction, mostly appreciation of
the care of the GPs. On the other hand, one-third of
the GPs (36%) experienced at least one strikingly
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negative reaction from a patient; their anger in most
cases could be interpreted as concern about the
willingness of their GP to continue their usage.
For each GP, we divided the sending of letters into
two parts with a 4-week interval; 39 GPs (71%) were
able to organize the evaluation consultations effi-
ciently within their daily practice, while six GPs
(11%) could not. The conversational advice to
motivate non-quitters for the second intervention
was well received by the GPs: 36 (67%) used them,
and 32 (59%) thought their consultations improved
by using them. Furthermore, 46 (83%) GPs indi-
cated the importance of sufficient conversational
advice for GPs in using this motivational strategy.
Most GPs (84%) considered the duration and
number of reduction steps of the tapering-off scheme
just right. Some recommendations were given to use
it more individually, especially for low-dose users,
e.g., no transfer to diazepam, fewer dosage-reduc-
tion steps, or only consultation by telephone. More-
over, 44 GPs (81%) would recommend colleagues to
taper patients themselves, of which 39 (75%) would
recommend our scheme. Satisfaction with the taper-
ing-off scheme was also reflected by the fact that two
out of three GPs used the tapering-off scheme for
patients outside the trial (6). Interestingly, 32 GPs
(78%) would encourage patients to take part in
group psychotherapy sessions to support tapering
off, although they also reported that these patients
were not easier to supervise, and our trial results also
did not support superiority over tapering off alone.
Discussion
A stepwise benzodiazepine reduction programme
was well received by GPs. Most GPs (82%) experi-
enced no increase in medical consumption. Possibi-
lities for individual tailoring may enhance
satisfaction of GPs participating in benzodiazepine
reduction programmes. The support and backup
given by the researchers, e.g., identifying long-term
users, preparing discontinuation letters, and defining
the taper schemes, may have increased the enthu-
siasm of GPs. It may be worthwhile to offer this
support to GPs when our programme is implemen-
ted in clinical practice.
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STEP 1: Discontinuation letter (preparation by researchers, sent by GP)
Exclusion criteria check (by GP)
Evaluation consultation (EC) by the GP No EC, patient does not want  
STEP 2: Dose reduction trial No trial, patient does not want
-current psychiatric treatment 
-drug or alcohol dependency  treatment 
-psychosis in medical  history 
-epilepsy 
-terminal disease 
-not mastering Dutch  language 
-individual GP reasons                            
(co-morbidity, psychosocial reasons, high age, 
transportation need to the GP ward, currently 
not in the practice)
Defining long-term benzodiazepine users (by researchers)  
Automatic extraction of demographic and prescription data from EMD (by researchers at GP practice)
Second letter, after 12 weeks, invitation for consultation (preparation by researchers, sent by GP)
Sending postal questionnaire to GP 2 months after the end of the step 2 interventions
Randomization (researchers)
Excluded
Included
GP taper scheme + group psychotherapy (by GP and psychotherapist)
GP taper scheme (by GP)
Usual care (by GP)
Figure 1. Operational flow chart of the Benzoredux programme.
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